Aspirin
Patent Foramen Ovale
Floatz Rating
BBB76/100
Confidence
Indicative
Sponsor
Assistance Publique - Hôpitaux de Paris
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05387954CT.gov PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years | — | Recruiting | — | — | — |
NCT05546320CT.gov Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Patent Foramen Ovale
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aspirin (this asset) | Assistance Publique - Hôpitaux de Paris | Approved | BBB · 76 |
| Rivaroxaban | Chinese Academy of Medical Sciences, Fuwai Hospital | P3 | BB |
| Warfarin | Columbia University | P4 | BB |
| Apixaban | Mayo Clinic | P3 | BB |
| Dabigatran | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Flecainide | Assistance Publique - Hôpitaux de Paris | P3 | B |
| Prasugrel | Columbia University | P3 | B |
| Beatrolol | Chinese Academy of Medical Sciences, Fuwai Hospital | P2 | B |
| Clopidogrel | Chinese Academy of Medical Sciences, Fuwai Hospital | P3 | NR |
Other indications for Aspirin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myocardial Infarction | — | P4 | A · 83 |
| Coronary Artery Disorder | — | P4 | BBB · 79 |
| Cardiovascular Disorder | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Aspirin in Patent Foramen Ovale. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/aspirin-patent-foramen-ovale
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →